Kala Pharmaceuticals raises $11.5m in Series A financing round
Kala said Crown Venture Fund is the new and lead investor who joined its existing investors including Lux Capital Management, Polaris Venture Partners and Third Rock Ventures. The
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The firm’s new platform is created to improve deployment and integration, and reduce infrastructure investments for adoption of BIandanalytics tools by healthcare organizations. In addition, BI-Clinical has developed
The patent entitled, ‘In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages,’ expands the DPC platform, broadly protecting the company’s next generation DPC polymer masking technology. The company